BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biliary Tract Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Biliary Tract Cancer\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05784688-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05784688)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of
  TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Adv
 anced Solid Tumors\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05784688
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06178445-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06178445)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: Efficac
 y and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously U
 ntreated HER2-positive Biliary Tract Cancer\nEstimated primary completion:
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06178445
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727176-2756@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT05727176)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2\, Cholangiocarcinoma.\nStudy: S
 tudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR
 2 Fusion or Rearrangement\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0572717
 6
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05948475-9067@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tinengotinib: Phase 3 readout est. (NCT05948475)
DESCRIPTION:Tinengotinib\, phase 3\, Cholangiocarcinoma.\nStudy: Study of T
 inengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-alter
 ed in Cholangiocarcinoma\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tinengotinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05948475
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06490107-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06490107)
DESCRIPTION:Durvalumab\, phase 2\, Biliary Tract Cancer.\nStudy: Durvalumab
  Combined With S-1 as Adjuvant Therapy of Resectable BTC\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06490107
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717464-2018@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06717464)
DESCRIPTION:Toripalimab\, phase 2\, Cholangiocarcinoma.\nStudy: Toripalimab
  Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients
  With Resectable Advanced Extrahepatic Biliary Tract Cancer\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06717464
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679399-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07679399)
DESCRIPTION:Durvalumab\, phase 2\, Biliary Tract Cancer.\nStudy: A Phase II
  Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed
  by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.\nEstimated pri
 mary completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07679399
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938321-2023@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06938321)
DESCRIPTION:Ivonescimab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Study
  of AK130 in Combination With AK112 for the Treatment of Advanced Biliary 
 Tract Cancer\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06938321
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978114-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06978114)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: A Study
  of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Bili
 ary Tract Cancer\nEstimated primary completion: May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06978114
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978114-2044@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06978114)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Biliary Tract Cancer.\nStud
 y: A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Adv
 anced Biliary Tract Cancer\nEstimated primary completion: May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0697811
 4
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548412-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06548412)
DESCRIPTION:Durvalumab\, phase 1/2\, Biliary Tract Cancer.\nStudy: CTX-009 
 With Gemcitabine\, Cisplatin\, and Durvalumab as First-line Therapy in Pat
 ients With Unresectable or Metastatic Biliary Tract Cancers\nEstimated pri
 mary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06548412
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548412-10870@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:tovecimig: Phase 1/2 readout est. (NCT06548412)
DESCRIPTION:tovecimig\, phase 1/2\, Biliary Tract Cancer.\nStudy: CTX-009 W
 ith Gemcitabine\, Cisplatin\, and Durvalumab as First-line Therapy in Pati
 ents With Unresectable or Metastatic Biliary Tract Cancers\nEstimated prim
 ary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tovecimig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06548412
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab in Combination With Propranolol and Chemotherapy for
  Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated pr
 imary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05451043
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159217-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07159217)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: Disitam
 ab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive 
 Advanced Biliary Tract Cancer\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07159217
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05342194-2018@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05342194)
DESCRIPTION:Toripalimab\, phase 3\, Cholangiocarcinoma.\nStudy: Toripalimab
  Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Adv
 anced ICC: a Phase III Study\nEstimated primary completion: 31 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05342194
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728410-2225@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT06728410)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Adva
 nced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearra
 ngement\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06728410
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06529718-2023@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06529718)
DESCRIPTION:Ivonescimab\, phase 2\, Biliary Tract Cancer.\nStudy: Testing I
 vonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients\nEstima
 ted primary completion: 3 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06529718
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05506943-10870@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:tovecimig: Phase 2/3 readout est. (NCT05506943)
DESCRIPTION:tovecimig\, phase 2/3\, Biliary Tract Cancer.\nStudy: A Study o
 f CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectab
 le Advanced\, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002
 )\nEstimated primary completion: 31 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tovecimig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05506943
URL:https://assetmemo.bio/drug/tovecimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1986@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Rilvegostomig\, phase 2\, Biliary Tract Cancer.\nStudy: Study o
 f Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Pa
 tients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary
  completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482893-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05482893)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Spevatam
 ig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted The
 rapy and/or ICI\, for the Treatment of Patients With Advanced Gastrointest
 inal Cancers\, Including Gastric\, Gastroesophageal Junction\, Pancreatic 
 Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05482893
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05874414-10941@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ezurpimtrostat: Phase 1/2 readout est. (NCT05874414)
DESCRIPTION:Ezurpimtrostat\, phase 1/2\, Cholangiocarcinoma with KRAS Mutat
 ion.\nStudy: Combination of GNS561 and Trametinib in Patients With Advance
 d KRAS Mutated Cholangiocarcinoma\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ezurpimtrostat#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0587
 4414
URL:https://assetmemo.bio/drug/ezurpimtrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study 
 of RP2 in Combination With Second-line Therapy in Patients With Locally Ad
 vanced or Metastatic HCC\nEstimated primary completion: 1 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780838-2225@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07780838)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Bilia
 ry or Cholangiocarcinoma\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pemigatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07780838
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786766-2225@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07786766)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusi
 on/Rearrangement-Positive Cholangiocarcinoma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 emigatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07786766
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439485-2225@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Pemazyre (Pemigatinib): Phase 1/2 readout est. (NCT06439485)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 1/2\, Cholangiocarcinoma.\nStudy
 : Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bev
 acizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion\nE
 stimated primary completion: 22 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06439485
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06001658-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06001658)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: Periope
 rative Gemcitabine\, Cisplatin\, and Pembrolizumab in Potentially Resectab
 le Biliary Tract Cancers\nEstimated primary completion: June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06001658
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467357-1986@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06467357)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: Phase 3
  Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing B
 iliary Tract Cancer\nEstimated primary completion: 12 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06467357
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685535-2018@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07685535)
DESCRIPTION:Toripalimab\, phase 2\, Cholangiocarcinoma.\nStudy: HAIC + DEB-
 TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocar
 cinoma\nEstimated primary completion: 30 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07685535
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841873-2201@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07841873)
DESCRIPTION:Zanidatamab\, phase 2\, Biliary Tract Cancer.\nStudy: Zanidatam
 ab Combined With Liposomal Irinotecan and Capecitabine for Second-line Tre
 atment of HER2-positive Unresectable Biliary Tract Tumors\nEstimated prima
 ry completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07841873
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850791-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07850791)
DESCRIPTION:Pembrolizumab\, phase 2\, Biliary Tract Cancer.\nStudy: A Prosp
 ective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Bi
 liary Tract Cancer\nEstimated primary completion: October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07850791
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854600-2023@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07854600)
DESCRIPTION:Ivonescimab\, phase 2\, Biliary Tract Cancer.\nStudy: A Phase I
 I Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conver
 sion Therapy for Biliary Tract Cancer\nEstimated primary completion: Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785
 4600
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582315-2044@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07582315)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Biliary Tract Cancer.\nStud
 y: A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Pati
 ents With Locally Advanced or Metastatic Biliary Tract Cancer After Failur
 e of Platinum-based Chemotherapy(PANKU-BTC01)\nEstimated primary completio
 n: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iza
 lontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07582315
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07606599-2282@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07606599)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Biliary Tract Cancer.\nStud
 y: A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patien
 ts With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cance
 r After Platinum-containing Chemotherapy Failure\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-brengitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07606599
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Durvalumab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy a
 nd Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of
 -care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated p
 rimary completion: 1 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Pembrolizumab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficac
 y and Safety of Zanidatamab With Standard-of-care Therapy Against Standard
 -of-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimate
 d primary completion: 1 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-2201@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy 
 and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-o
 f-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated 
 primary completion: 1 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765433-2023@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 2/3 readout est. (NCT07765433)
DESCRIPTION:Ivonescimab\, phase 2/3\, Biliary Tract Cancer.\nStudy: Testing
  the Addition of Ivonescimab Combined With Standard Chemotherapy Compared 
 to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Ad
 vanced Biliary Tract Cancer\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07765433
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109779-1986@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06109779)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: Rilvego
 stomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After R
 esection (ARTEMIDE-Biliary01)\nEstimated primary completion: 2 January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109779
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221253-1986@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT07221253)
DESCRIPTION:Rilvegostomig\, phase 3\, Biliary Tract Cancer.\nStudy: A Study
  of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment
  of Biliary Tract Cancer (ARTEMIDE-Biliary02)\nEstimated primary completio
 n: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilv
 egostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07221253
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269158-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT07269158)
DESCRIPTION:Durvalumab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Phase 
 IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Mainten
 ance Therapy in Patients With Advanced Biliary Tract Cancer\nEstimated pri
 mary completion: September 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07269158
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269158-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07269158)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Pha
 se IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Main
 tenance Therapy in Patients With Advanced Biliary Tract Cancer\nEstimated 
 primary completion: September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07269158
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428409-1973@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06428409)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinic
 al Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestin
 al Cancers (MK-9999-02A)\nEstimated primary completion: 16 October 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06428409
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328919-9067@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tinengotinib: Phase 3 readout est. (NCT07328919)
DESCRIPTION:Tinengotinib\, phase 3\, Cholangiocarcinoma.\nStudy: Efficacy a
 nd Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patien
 ts With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/R
 earrangements or Mutations\nEstimated primary completion: 31 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tinengotinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07328919
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710885-2756@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT07710885)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3\, Biliary Tract Cancer.\nStudy:
  Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer\nEst
 imated primary completion: 30 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07710885
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639528-2756@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301210
DTEND;VALUE=DATE:20301211
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT07639528)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2\, Cholangiocarcinoma.\nStudy: P
 reoperative Durvalumab\, Cisplatin\, Gemcitabine With or Without Futibatin
 ib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangio
 carcinoma\, OPTIC Trial\nEstimated primary completion: 10 December 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076395
 28
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862998-2225@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310225
DTEND;VALUE=DATE:20310226
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07862998)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants
  With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Wi
 th FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic 
 Therapy\nEstimated primary completion: 25 February 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07862998
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938645-1959@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20330131
DTEND;VALUE=DATE:20330201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07938645)
DESCRIPTION:Durvalumab\, phase 2\, Biliary Tract Cancer.\nStudy: PARP Inhib
 ition for Biliary Tract Cancer With Mutations in Core and Non-Core Homolog
 ous Recombination Deficiency Genes\nEstimated primary completion: January 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07938645
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745296-2201@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20330702
DTEND;VALUE=DATE:20330703
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT07745296)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Investiga
 ting Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer\nE
 stimated primary completion: 2 July 2033. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07745296
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745296-2756@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20330702
DTEND;VALUE=DATE:20330703
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT07745296)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3\, Biliary Tract Cancer.\nStudy:
  Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract
  Cancer\nEstimated primary completion: 2 July 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07745296
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
